# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Henry Holliday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI007-SYN
- Date: 2026-08-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Martin Beaumont, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

End-of-treatment review after six months. **S**

## History of present illness

Mr. Holliday returns five days after his last dose. He completed all 182 doses by video-observed therapy: 56 in the intensive phase and 126 in the continuation phase, with the one dose held during the stomach illness in the spring added at the end. The cultures from the third week and from the two-month visit both grew nothing, so the continuation phase stayed at four months. He has had no cough, fever, night sweats, or weight loss for months, and he has gained 7.5 kg. The repeat liver tests planned two weeks after the sick visit, and the monthly tests in the fourth and fifth months, were not drawn; he reported no hepatitis symptoms on any video call. Since the party in the spring he has had a drink or two at most once a week and no heavy drinking. He sees his counselor once a month. **S**

| Element | Detail |
|---|---|
| Treatment | All 182 doses completed by video-observed therapy |
| Cultures | Third-week and two-month cultures negative |
| Weight | 65.5 kg, up 7.5 kg since diagnosis |
| Alcohol | AUDIT-C 3; no heavy drinking since the spring |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No cough, sputum, hemoptysis, or breathlessness |
| Constitutional | Negative | No fever, night sweats, or weight loss |
| Gastrointestinal | Negative | No nausea, abdominal pain, or jaundice |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood good; PHQ-9 3; no thoughts of suicide or self-harm |

5 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 65.5 kg; BMI 20.7 kg/m². All vital signs are synthetic.

ALT: 30 U/L; AST: 28 U/L; Total bilirubin: 0.6 mg/dL; Hemoglobin: 14.4 g/dL; AUDIT-C: 3; PHQ-9: 3. All results are synthetic.

## Change since baseline

- ALT: 34 U/L at baseline, 30 U/L at this visit **S**
- AST: 38 U/L at baseline, 28 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.6 mg/dL at this visit **S**
- Hemoglobin: 12.6 g/dL (low) at baseline, 14.4 g/dL at this visit **S**
- AUDIT-C: 9 at baseline, 3 at this visit **S**
- PHQ-9: 6 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 65.5 kg, BMI 20.7 |
| Eyes | No icterus |
| Respiratory | Clear, with no crackles |
| Abdomen | Liver not enlarged |
| Neurological | Normal sensation in the feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Drug-susceptible pulmonary tuberculosis, treatment completed** (A15.0). Treatment completed, with culture conversion and a full clinical response. The chest X-ray today shows the cavity closed, with residual scarring in the right upper lobe. End-of-treatment ALT 30, AST 28, bilirubin 0.6, and hemoglobin 14.4, all normal. Dr. Navarro reviewed the results by message today and advises no routine follow-up after treatment. **S**
   - No further tuberculosis medicine.
   - Return the same day for cough lasting more than two weeks, fever, night sweats, or weight loss, which could mean relapse.
   - Keep today's chest X-ray as the baseline for any future comparison.
   - Health department notified that treatment is complete.
2. **Alcohol use disorder, mild, improving** (F10.10). Low-risk drinking since the spring. AUDIT-C 3, PHQ-9 3. Safety reviewed: no thoughts of suicide. **S**
   - Continue monthly counseling.
   - Keep to no more than two drinks on any day.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | At least monthly during treatment | Completed today | No symptoms |
| Examination | Weight | At least monthly during treatment | Completed today | 65.5 kg |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | None reported at any observed dose |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline, at two weeks, then monthly because of alcohol use | Completed today | ALT 30, AST 28 U/L, bilirubin 0.6 mg/dL, all normal at the end of treatment |
| Laboratory | Liver tests after the sick visit and in months four and five | Two weeks after the sick visit, then monthly | Deferred | Not drawn: no visit was scheduled between the sick visit and the end of treatment, and no standing order was placed. He reported no hepatitis symptoms on daily video calls, and the end-of-treatment tests are normal, so no harm is evident. Corrective action: standing monthly liver-test orders at the start of treatment for every patient with a risk factor |
| Laboratory | Hemoglobin | At the end of treatment when low at baseline | Completed today | 14.4 g/dL, up from 12.6 at diagnosis |
| Laboratory | Sputum AFB smear and culture | Monthly until two consecutive cultures are negative | Completed today | Two consecutive negative cultures (third week and two months); no further sputum needed |
| Laboratory | Two-month sputum culture | At the end of the intensive phase; decides the continuation length in cavitary disease | Completed today | No growth; continuation phase kept at four months |
| Imaging | Chest X-ray | At diagnosis; at two months only if the first cultures were negative; at the end of treatment as a new baseline | Completed today | Cavity closed; residual right upper lobe scarring |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | All 182 doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy; pyridoxine stopped with isoniazid |
| Referral | Notification of treatment completion to the health department | At the end of treatment | Completed today | Sent today |
| Survey | Alcohol use (AUDIT-C for the past month) | Every visit | Completed today | AUDIT-C 3 for the past month |
| Self-management | Brief counseling about alcohol and liver risk | Every visit | Completed today | Low-risk limits agreed now that treatment is over |
| Referral | Counseling with a substance-use counselor | Every one to two weeks during treatment | Completed today | Monthly |
| Survey | Depression screen (PHQ-9) | At diagnosis and at the end of treatment | Completed today | PHQ-9 3, item 9 scored 0 |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide |
| Referral | Infectious diseases review | At two months and at the end of treatment | Completed today | Dr. Navarro reviewed the end-of-treatment results by message; no routine follow-up |

## Goal progress

- Complete 182 doses of treatment under video-observed therapy within six months. Outcome by 2026-08-18: All 182 doses completed: 56 in the intensive phase and 126 in the continuation phase, with one dose held during a stomach illness and made up at the end. **S**
- Sputum culture negative at two months. Outcome by 2026-08-18: Two-month culture showed no growth, so the continuation phase stayed at four months. **S**
- No alcohol during treatment, to protect his liver. Outcome by 2026-08-18: Not fully met: no drinking for most of the six months, with one evening of heavy drinking at a party about three months into treatment; AUDIT-C 3 at the end. **S**
- Return to work once he is no longer infectious. Outcome by 2026-03-17: Released from home isolation after three negative sputum smears and back at work four weeks into treatment. **S**
- Weight back to at least 64 kg by the end of treatment. Outcome by 2026-08-18: 65.5 kg at the end of treatment, from 58.0 kg at diagnosis. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Adult preventive visit in about a month. Same-day visit for symptoms of relapse. **S**
- Next scheduled visit 2026-09-22: adult preventive visit. **S**
